Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1651-1655

  Dollner, Ralph ^a   Granzow, Christof ^b   Neudert, Marcus ^c   Dietz, Andreas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Chemosensitivity testing; Drug combinations; Head and neck carcinoma; HNSCC; Tumor stroma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; FLUOROURACIL;

CHEMOREACTIVITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLONY FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; EPITHELIUM CELL; EX VIVO STUDY; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; KB CELLS; STROMAL CELLS; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 33645836544     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Adelstein DJ: Systemic chemotherapy for squamous cell head and neck cancer. Exp Opin Pharmacother 4: 2151-2163, 2003.
2. Au JL, Rustum YM, Ledesma EJ, Mittelman A and Creaven PJ: Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinoma. Cancer Res 42: 2930-2937, 1982.
3. Desoize B, Berthoit G, Manot L, Coninx P and Dumont P: Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration. Eur J Cancer 32A: 1734-1738, 1996.
4. Dietz A, Weber A, Dollner R and Hildebrandt G: Decision making in non resectable head and neck tumours. Laryngorhinootologic 84: 200-206, 2005.
5. Dollner R, Granzow C, Helmke BM, Ruess A, Schad A and Dietz A: The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma. Anticancer Res 24: 325-331, 2004.
6. Dollner R, Granzow C, Werner JA and Dietz A: Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 27: 310-315, 2004.
7. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N and Marty M: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042, 1993.
8. Granzow C, Kopun M and Kroeber T: Riboflavin-mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Cancer Res 55: 4837-4843, 1995.
9. Heuser M, Kopun M, Rittgen W and Granzow C: Cytotoxicity determination without photochemical artifacts. Cancer Lett 223: 57-66, 2005.
10. Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa, Kimura K and Smyth RD: Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28: 208-215, 1988.
11. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM and Shah J: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24: 437-442, 2002.
12. Stausbøl-Grøn B, Nielsen OS, Moller BS and Overgaard J: Selective assessment of in vitro radiosensitivity of tumour cells and fibroblasts from single tumour biopsies using immunocytochemical identification of colonies in the soft agar clonogenic assay. Radiother Oncol 37: 87-99, 1995.